Pharmacoepidemiology and population impact of drugs

The team is devoted to Pharmacoepidemiology, which studies medical drugs and devices at the level of populations. The researches conducted aim to characterize drug patterns of use and potential misuses, assess potential health hazards associated with this use in real-life, and ensure that the beneficial effect proven in clinical trials is confirmed in everyday use. The final aim is to quantify the actual public health impact of marketed medicines.

Objectives

The challenge is to identify patterns of use of medical drugs that compromise their beneficial effects on public health. The prerequisite for a medical drug to be marketed is that the information obtained from clinical trials, i.e. in experimental conditions of use, allows considering that the benefit it will provide to public health outweighs the burden of its unavoidable adverse effects. Once a medical drug gets marketed, it is no longer used in this experimental, controlled, setting but in real-life “natural” conditions, in which some specific patterns of uses or some uses in specific populations can convey increased risks for public health. These uses and associated risks can alter drastically the benefit-risk balance of the drug and its impact on population health. The objective of the team is to identify such situations; the key aspects of the researches conducted in this purpose are the following:

  • the more a drug is used, the most important its impact on public health (positive or negative) can be
  • this impact, in terms of risk, can be increased when the populations using the drug present with specific frailties, as in the case of cancer for instance
  • in situations of massive use, even mild to moderate effects on health induced by drugs can convey a tremendous impact on public health
  • such mild to moderate changes (beneficial or detrimental) are the most difficult to identify and quantify in an real-life setting.

Conducting such researches consequently implies, aside to the performing of studies applied to specific fields of health, to continuously develop and assess new methods for the study of drugs in real-life setting.

Details

Centre de recherche INSERM U1219
Université de Bordeaux – ISPED case 11
146 rue Léo-Saignat
33076 BORDEAUX cedex
Tél : +33 (0)5 57 57 95 12

 

  • Director:
    Directeur – Equipe Pharmaco-épidémiologie

    Médecin spécialiste en Santé Publique, Antoine Pariente a complété sa formation médicale en effectuant un cursus de spécialisation complémentaire en pharmacologie et évaluation des thérapeutiques. Parallèlement a ses études de médecine, il a suivi une formation à la recherche en santé publique  et obtenu un Master en Epidémiologie et biostatistique (Université de Bordeaux) avant de compléter une Thèse d’Université en Pharmaco-épidémiologie (Université de Bordeaux – Université de Montréal). Ses axes de recherche principaux sont la pharmaco-épidémiologie des personnes âgées et des maladies chroniques, et la détection de signaux en pharmacovigilance.

    Graduated from the medical faculty of Bordeaux as an MD with specialisation in Public Health, A. Pariente completed his medical training with a complementary specialisation in Pharmacology. Concomitantly to his medical studies, he obtained a Master Degree in Public Health at the Bordeaux Institute of Public Health and further completed his research training with a PhD in pharmacoepidemiology (University of Bordeaux-University of Montreal). His main research axes in pharmacoepidemiology focus on the elder and chronic diseases ; they focus in methods and biases for safety signal detection from spontaneous reporting in pharmacovigilance.

     

  • Contact: Marie-Annick Gauvrit


Informations

Research areas

  • Pharmacoepidemiology of psychotropic drugs
  • Pharmacoepidemiology of cancer drugs
  • Research, development and assessment of new methods applied to pharmacoepidemiology


Main publications

  1. Billioti de Gage S, Moride Y, Ducruet T, Kurth T, Verdoux H, Tournier M, Pariente A, Bégaud B. Benzodiazepine use and risk of Alzheimer’s disease: case-control study. 2014;349:g5205.
  2. Billioti de Gage S, Begaud B, Bazin F, Verdoux H, Dartigues JF, Peres K, Kurth T, Pariente A. Benzodiazepine use and risk of dementia: prospective population based study. BMJ 2012;345:e6231.
  3. Dauvilliers Y, Arnulf I, Lecendreux M, Monaca Charley C, Franco P, Drouot X, d’Ortho MP, Launois S, Lignot S, Bourgin P, Nogues B, Rey M, Bayard S, Scholz S, Lavault S, Tubert-Bitter P, Saussier C, Pariente A; Narcoflu-VF study group. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain. 2013;136:2486-96.
  4. Pariente A, Fourrier-Réglat A, Ducruet T, Farrington P, Béland SG, Dartigues JF, Moore N, Moride Y. Antipsychotic use and myocardial infarction in older patients with treated dementia. Archives of internal medicine 2012;172:648-53.
  5. Pariente A, Fourrier-Réglat A, Bazin F, Ducruet T, Dartigues JF, Dragomir A, Perreault S, Moore N, Moride Y. Effect of treatment gaps in elderly patients with dementia treated with cholinesterase inhibitors. Neurology. 2012;78:957-63.

Members


logo_ISPED logo_Université-de-Bordeaux logo_SFR-santepublique-societe logo_CHU-Bordeaux logo_Institut-Bergonie logo_INRIA logo_ANRS logo_ARS logo_Charles-Perrens logo_IFSTTAR logo_HONcode